Bioequivalence evaluation of 2 brands of cefuroxime axetil 250 mg tablets in healthy human volunteers
To assess the bioequivalence of 2 oral cefuroxime axetil (250 mg) tablets formulation. The reference preparation was Zinadol/Glaxo Wellcome, England, while the test preparation was cefuroxime axetil/Pharmathen, Athens, Greece. The study was an open, randomized, 2-period, 2-sequence, 2-treatment cros...
Saved in:
Published in | International journal of clinical pharmacology and therapeutics Vol. 42; no. 7; p. 367 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.07.2004
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | To assess the bioequivalence of 2 oral cefuroxime axetil (250 mg) tablets formulation. The reference preparation was Zinadol/Glaxo Wellcome, England, while the test preparation was cefuroxime axetil/Pharmathen, Athens, Greece.
The study was an open, randomized, 2-period, 2-sequence, 2-treatment crossover, involving 24 healthy male and female volunteers. All volunteers completed the study. Cefuroxime axetil plasma concentrations were measured utilizing a sensitive, reproducible and accurate HPLC method. Care was taken through the collection and analysis of the samples due to instability of cefuroxime axetil in light. Pharmacokinetic parameters used to assess bioequivalence were AUC(0-last), AUC(0-inf) for the extent of absorption and Cmax and tmax for the rate of absorption. Statistical evaluation of Cmax, AUC(0-last), and AUC(0-inf) was done using 2-way analysis of variance (ANOVA) after semilogarithmic transformation. Tmax values were tested using the distribution-free Hodges-Lehman interval.
The parametric 90% confidence intervals for ratio T/R ranged from 98.91-111.65% (point estimate 105.09%) for AUC(0-last), 99.41-111.78% (point estimate 105.41%) for AUC(0-inf) and 87.61-102.89% (point estimate 94.95%) for Cmax, respectively. Based on the results of tmax, K(el) and t(1/2) there were no statistically significant differences.
The 2 cefuroxime axetil preparations, examined in accordance with the European Union bioequivalence requirements, are equivalent with respect to rate and extent of absorption. |
---|---|
AbstractList | To assess the bioequivalence of 2 oral cefuroxime axetil (250 mg) tablets formulation. The reference preparation was Zinadol/Glaxo Wellcome, England, while the test preparation was cefuroxime axetil/Pharmathen, Athens, Greece.
The study was an open, randomized, 2-period, 2-sequence, 2-treatment crossover, involving 24 healthy male and female volunteers. All volunteers completed the study. Cefuroxime axetil plasma concentrations were measured utilizing a sensitive, reproducible and accurate HPLC method. Care was taken through the collection and analysis of the samples due to instability of cefuroxime axetil in light. Pharmacokinetic parameters used to assess bioequivalence were AUC(0-last), AUC(0-inf) for the extent of absorption and Cmax and tmax for the rate of absorption. Statistical evaluation of Cmax, AUC(0-last), and AUC(0-inf) was done using 2-way analysis of variance (ANOVA) after semilogarithmic transformation. Tmax values were tested using the distribution-free Hodges-Lehman interval.
The parametric 90% confidence intervals for ratio T/R ranged from 98.91-111.65% (point estimate 105.09%) for AUC(0-last), 99.41-111.78% (point estimate 105.41%) for AUC(0-inf) and 87.61-102.89% (point estimate 94.95%) for Cmax, respectively. Based on the results of tmax, K(el) and t(1/2) there were no statistically significant differences.
The 2 cefuroxime axetil preparations, examined in accordance with the European Union bioequivalence requirements, are equivalent with respect to rate and extent of absorption. |
Author | Michalea, S Kontopoulos, G Pistos, C Georgarakis, M Kalovidouris, M |
Author_xml | – sequence: 1 givenname: C surname: Pistos fullname: Pistos, C email: cpistos@ilsgr.com organization: Integrated Laboratory Services, Athens, Greece. cpistos@ilsgr.com – sequence: 2 givenname: S surname: Michalea fullname: Michalea, S – sequence: 3 givenname: M surname: Kalovidouris fullname: Kalovidouris, M – sequence: 4 givenname: G surname: Kontopoulos fullname: Kontopoulos, G – sequence: 5 givenname: M surname: Georgarakis fullname: Georgarakis, M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15605688$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j0tOwzAUAL0ooh-QOAHyBQK2Ezv2EiIoSJXoAtbVi_1MjBKnJE7V3h4QsJpZjTRLMot9REKuOLuRBS9uq-22ELkqZ2TBTKEybpSck-U4fjAmpCzNOZlzqZhUWi8I3oceP6dwgBajRYrfMkEKfaS9p4LWA0Q3_rhFPw39MXRI4YgptFRIRrt3mqBuMY00RNogtKk50WbqINJD304xIQ7jBTnz0I54-ccVeXt8eK2ess3L-rm622RWlCZlmkvQWoK3AFIaB0p7ROt0nYtcuxK4Nw5rxY1hhULrlTGQc1ZaY4SzXKzI9W93P9Udut1-CB0Mp93_r_gCNaFXmg |
CitedBy_id | crossref_primary_10_1002_bmc_465 crossref_primary_10_3109_15569527_2015_1067817 crossref_primary_10_1007_s13738_021_02210_2 crossref_primary_10_1111_j_1759_8893_2011_00059_x |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.5414/CPP42367 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 15605688 |
Genre | Comparative Study Clinical Trial Randomized Controlled Trial Journal Article |
GroupedDBID | --- .GJ 36B 3V. 53G 5GY 7X7 88E 8FI 8FJ ABJNI ABUWG ACGFO ACGFS ADBBV AENEX AFFNX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BPHCQ BVXVI CCPQU CGR CUY CVF DLWAR EBS ECM EIF EJD EMB EMOBN F5P FYUFA HMCUK M1P MK0 NPM P2P PQQKQ PROAC PSQYO SJN SV3 UKHRP VDS ZGI ZXP ~4P |
ID | FETCH-LOGICAL-c279t-815a885afcaa559da68feecd8b3238d7a1f9deb6199046ecf699a3107c992dc12 |
ISSN | 0946-1965 |
IngestDate | Sat Sep 28 08:40:12 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c279t-815a885afcaa559da68feecd8b3238d7a1f9deb6199046ecf699a3107c992dc12 |
PMID | 15605688 |
ParticipantIDs | pubmed_primary_15605688 |
PublicationCentury | 2000 |
PublicationDate | 2004-07-01 |
PublicationDateYYYYMMDD | 2004-07-01 |
PublicationDate_xml | – month: 07 year: 2004 text: 2004-07-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | International journal of clinical pharmacology and therapeutics |
PublicationTitleAlternate | Int J Clin Pharmacol Ther |
PublicationYear | 2004 |
SSID | ssj0025579 |
Score | 1.7524217 |
Snippet | To assess the bioequivalence of 2 oral cefuroxime axetil (250 mg) tablets formulation. The reference preparation was Zinadol/Glaxo Wellcome, England, while the... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 367 |
SubjectTerms | Administration, Oral Adult Anti-Bacterial Agents - blood Anti-Bacterial Agents - pharmacokinetics Area Under Curve Cefuroxime - analogs & derivatives Cefuroxime - blood Cefuroxime - pharmacokinetics Chromatography, High Pressure Liquid Cross-Over Studies Female Half-Life Humans Male Tablets Therapeutic Equivalency Time Factors |
Title | Bioequivalence evaluation of 2 brands of cefuroxime axetil 250 mg tablets in healthy human volunteers |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15605688 |
Volume | 42 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELa2cOGCypvykA-olzTQuHZiHwGBKiqqHLZSb5WfVaTdzQJZqcu_4Z8yjp3XChBwiaJ4ZSX-PntnRjPfIPSKS6aYFTrNj5UDB0XDliK5TXMD_y7MggHBfTXy5_P89IJ-umSXs9mPUdbSplGv9fdf1pX8D6rwDHD1VbL_gGw_KTyAe8AXroAwXP8K43dVbb9sKpiy3Z-Dcrc3AUkCjrDPd_WJ49ZtvtY31dIm8sY21SIBmyRZXieNr5xq2pzYUBG5jV37_KkFax7z4zvzdRo_HKlO9AWW60EKe9tlZ3YFXr35Xno9g2-TGG2bvr-wchKNPZMLXyfYCh1OIrdnXnVhXW8WddfyfRS7oH2eax-EpHnqNQ3H5zElI94Vo8P1JDTu2D30fSNzLyZclpTs_ATgWi9b8H3BOMtDB8E_j-7Ib3dDe2iv4L43yLkPB0WPnrEo5hg_I6gb-xd6071O2_cpTLHjubQWzHwf3Y2uB34beHQPzezqPjosA2DbIzwfIXWED3E5gvIBslOy4YFsuHaY4EA2fz-QDQeyYSAbXl7jSDZcrXAkG27JhgeyPUQXHz_M35-msUdHqkkhmpRnTHLOpNNSgnNqZM6dtdpwdQLGoClk5oSxCtx0cUxzq10uhASXotBCEKMz8gjdWtUr-wThgjApDTWFBR9XZVwQqiw1glNFMuf0U_Q4LN_VOgixXHULe_DbkWfozsC75-i2g51vX4AZ2aiXLZQ_ATF7d7E |
link.rule.ids | 780 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bioequivalence+evaluation+of+2+brands+of+cefuroxime+axetil+250+mg+tablets+in+healthy+human+volunteers&rft.jtitle=International+journal+of+clinical+pharmacology+and+therapeutics&rft.au=Pistos%2C+C&rft.au=Michalea%2C+S&rft.au=Kalovidouris%2C+M&rft.au=Kontopoulos%2C+G&rft.date=2004-07-01&rft.issn=0946-1965&rft.volume=42&rft.issue=7&rft.spage=367&rft_id=info:doi/10.5414%2FCPP42367&rft_id=info%3Apmid%2F15605688&rft_id=info%3Apmid%2F15605688&rft.externalDocID=15605688 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-1965&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-1965&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-1965&client=summon |